Follow
Antonia Dimitrakopoulou-Strauss
Antonia Dimitrakopoulou-Strauss
Verified email at dkfz.de - Homepage
Title
Cited by
Cited by
Year
PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy
U Haberkorn, LG Strauss, A Dimitrakopoulou, R Engenhart, F Oberdorfer, ...
Journal of Nuclear Medicine 32 (8), 1485-1490, 1991
3601991
Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry.
U Haberkorn, LG Strauss, CH Reisser, D Haag, A Dimitrakopoulou, ...
Journal of nuclear medicine: official publication, Society of Nuclear …, 1991
3201991
Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas
MHM Schwarzbach, A Dimitrakopoulou-Strauss, F Willeke, U Hinz, ...
Annals of surgery 231 (3), 380-386, 2000
2362000
SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors
C Kratochwil, M Stefanova, E Mavriopoulou, T Holland-Letz, ...
Molecular Imaging and Biology 17, 313-318, 2015
2052015
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas
M Henze, A Dimitrakopoulou-Strauss, S Milker-Zabel, J Schuhmacher, ...
Journal of Nuclear Medicine 46 (5), 763-769, 2005
2032005
Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy
U Haberkorn, LG Strauss, A Dimitrakopoulou, E Seiffert, F Oberdorfer, ...
Journal of Nuclear Medicine 34 (1), 12-17, 1993
2011993
Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
H Anwar, C Sachpekidis, J Winkler, A Kopp-Schneider, U Haberkorn, ...
European journal of nuclear medicine and molecular imaging 45, 376-383, 2018
1812018
The role of quantitative 18F-FDG PET studies for the differentiation of malignant and benign bone lesions
A Dimitrakopoulou-Strauss, LG Strauss, T Heichel, H Wu, C Burger, ...
Journal of Nuclear Medicine 43 (4), 510-518, 2002
1812002
Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
S Koukouraki, LG Strauss, V Georgoulias, M Eisenhut, U Haberkorn, ...
European journal of nuclear medicine and molecular imaging 33, 1115-1122, 2006
1772006
Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading
A Dimitrakopoulou-Strauss, LG Strauss, M Schwarzbach, C Burger, ...
Journal of Nuclear Medicine 42 (5), 713-720, 2001
1762001
Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F] fluoro-L-dopa with 18F-FDG and 15O-water using compartment and noncompartment analysis
A Dimitrakopoulou-Strauss, LG Strauss, C Burger
Journal of Nuclear Medicine 42 (2), 248-256, 2001
1762001
Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
S Koukouraki, LG Strauss, V Georgoulias, J Schuhmacher, U Haberkorn, ...
European journal of nuclear medicine and molecular imaging 33, 460-466, 2006
1572006
Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI …
MT Freitag, JP Radtke, A Afshar-Oromieh, MC Roethke, BA Hadaschik, ...
European journal of nuclear medicine and molecular imaging 44, 776-787, 2017
1542017
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
E Zamagni, C Nanni, F Gay, A Pezzi, F Patriarca, M Bellò, I Rambaldi, ...
Leukemia 30 (2), 417-422, 2016
1382016
68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG
A Dimitrakopoulou-Strauss, P Hohenberger, U Haberkorn, HR Mäcke, ...
Journal of Nuclear Medicine 48 (8), 1245-1250, 2007
1362007
Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study
C Sachpekidis, L Larribere, L Pan, U Haberkorn, ...
European journal of nuclear medicine and molecular imaging 42, 386-396, 2015
1342015
Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives
A Dimitrakopoulou-Strauss, L Pan, C Sachpekidis
European journal of nuclear medicine and molecular imaging 48, 21-39, 2021
1252021
Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas
MHM Schwarzbach, U Hinz, A Dimitrakopoulou-Strauss, F Willeke, ...
Annals of surgery 241 (2), 286-294, 2005
1252005
Comparison of 18F-FDG PET/CT and PET/MRI in patients with multiple myeloma
C Sachpekidis, J Hillengass, H Goldschmidt, J Mosebach, L Pan, ...
American journal of nuclear medicine and molecular imaging 5 (5), 469, 2015
120*2015
Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience
P Ströbel, R Bargou, A Wolff, D Spitzer, C Manegold, ...
British journal of cancer 103 (2), 196-200, 2010
1172010
The system can't perform the operation now. Try again later.
Articles 1–20